ERBB2 and lung cancer: With the development of molecular subtype in lung cancer, NSCLC patients with EGFR-WT had been identified to carry several new “driver mutations”, including KRAS, HER2, and BRAF mutations, as well as ALK, ROS1, and RET gene fusion.